Copyright
©The Author(s) 2023.
World J Clin Cases. May 16, 2023; 11(14): 3114-3127
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3114
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3114
Ref. | In vitro/invivo | Gene mutation/editing method | Observed alterations |
[80-82] | BTBR T + tf/J (BTBR), Fmr1 knockout, C57BL/6 mice | mGluR5 | Rescued the exaggerated repetitive behaviours in mice caused by fragile X syndrome |
[83] | HEK293 cell and Human iPSC (BCRT cell line) | MECP2 | Reversal of ASD-associated Rett syndrome-like symptoms |
[84] | RX41X iPSC and NOD/SCID female mice | SHANK2 | Positive impact on nerve cells was reported like an increase in synapse number, dendritic complexity and length |
[85] | C57BL/6 mice, Ube3am-/p+ mice and Ube3am-/pYFP mice on the C57Bl/6 | Antisense transcript of UBE3A | Rescued the anatomical and behavioural phenotypes in a mouse model of Angelman syndrome |
[86] | HEK293FT cells | FMR1 | Fragile X syndrome improved by knocking out the CGG |
[89] | Mef2c L35P knock-in mouse | MEF2C | Reversal of autistic-like behaviour |
- Citation: Sandhu A, Kumar A, Rawat K, Gautam V, Sharma A, Saha L. Modernising autism spectrum disorder model engineering and treatment via CRISPR-Cas9: A gene reprogramming approach. World J Clin Cases 2023; 11(14): 3114-3127
- URL: https://www.wjgnet.com/2307-8960/full/v11/i14/3114.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i14.3114